LINC00152 was used as a competitive endogenous RNA to make oxaliplatin-resistant colon cancer-sponging miR-193a-3p via the LINC00152/miR-193a-3p/erbb4/Akt signaling axis (39). Here, ERBB4 is linked to colonic neoplasm.